CoChat

Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans

Open access

The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index; 19 of the 65 sources its claims cite were checked for support.

Abstract

Aggregation of amyloid-β (Aβ) as toxic oligomers and amyloid plaques within the brain appears to be the pathogenic event that initiates Alzheimer's disease (AD) lesions. One therapeutic strategy has been to reduce Aβ levels to limit its accumulation. Activation of certain neurotransmitter receptors can regulate Aβ metabolism. We assessed the ability of serotonin signaling to alter brain Aβ levels and plaques in a mouse model of AD and in humans. In mice, brain interstitial fluid (ISF) Aβ levels were decreased by 25% following administration of several selective serotonin reuptake inhibitor (SSRI) antidepressant drugs. Similarly, direct infusion of serotonin into the hippocampus reduced ISF Aβ levels. Serotonin-dependent reductions in Aβ were reversed if mice were pretreated with inhibitors of the extracellular regulated kinase (ERK) signaling cascade. Chronic treatment with an SSRI, citalopram, caused a 50% reduction in brain plaque load in mice. To test whether serotonin signaling could impact Aβ plaques in humans, we retrospectively compared brain amyloid load in cognitively normal elderly participants who were exposed to antidepressant drugs within the past 5 y to participants who were not. Antidepressant-treated participants had significantly less amyloid load as quantified by positron emission tomography (PET) imaging with Pittsburgh Compound B (PIB). Cumulative time of antidepressant use within the 5-y period preceding the scan correlated with less plaque load. These data suggest that serotonin signaling was associated with less Aβ accumulation in cognitively normal individuals.

Overview

CoChat Summary

TL;DR

Serotonin signaling, including via SSRI antidepressants, acutely lowers brain interstitial fluid amyloid-β (Aβ) in a mouse model of Alzheimer’s disease through an ERK-dependent mechanism and chronically reduces plaque burden. In cognitively normal older adults, retrospective antidepressant use within the past 5 years was associated with lower Pittsburgh Compound B PET amyloid load.

Key findings

  • In PS1APP mice, SSRIs fluoxetine, desvenlafaxine, and citalopram reduced interstitial fluid (ISF) Aβ by 25% at 24 h; citalopram at 5 and 10 mg/kg reduced ISF Aβ by 16% and 26%, respectively. Direct hippocampal serotonin infusion reduced ISF Aβ by 35% over 8 h without changing Aβ elimination half-life (~1 h).
  • ERK signaling was required: MEK/ERK inhibitors increased ISF Aβ by 40% and blocked citalopram’s Aβ-lowering effect; citalopram increased activated pERK2 and α-secretase activity.
  • Chronic citalopram (8 mg/kg/day for 4 months) reduced cortical and hippocampal plaque load by 62% and 50%, respectively, and reduced CSF Aβ40 and Aβ42 by 28% and 55%.
  • In 186 cognitively normal participants, those treated with antidepressants within the past 5 years (mean exposure 34.5 months) had lower mean cortical binding potential (0.06 ± 0.023) than untreated participants (0.13 ± 0.019; Wilcoxon rank sum P = 0.01), and longer antidepressant duration correlated with lower amyloid load (ρ = −0.298, P = 0.02).

Methods

  • Mouse studies used 2- to 3-month-old and 12-month-old PS1APP transgenic mice with unilateral hippocampal microdialysis to measure ISF Aβ dynamically; drugs were given i.p. or by reverse microdialysis, with ELISA, histology, enzymatic activity assays, and quantitative PCR.
  • Chronic mouse treatment began at 3 months of age with vehicle or citalopram in drinking water for 4 months, followed by histological plaque quantification and biochemical Aβ measurements.
  • Human study retrospectively compared 186 cognitively normal participants (CDR = 0) who underwent Pittsburgh Compound B PET amyloid imaging; antidepressant exposure within the past 5 years was assessed by structured interview, and treated vs untreated groups were compared with Wilcoxon rank-sum tests and Spearman correlation.

Limitations

  • The paper states that the findings are preliminary and unreplicated, and that a randomized controlled clinical trial would be needed to determine whether SSRIs have a beneficial effect on cerebral amyloid burden in humans.
  • The paper states that the retrospective human study could not separate the effects of antidepressant exposure from depression itself, and that excluding participants with CDR greater than zero may have produced selection bias.
  • The paper states that a direct causal relation between antidepressants and plaque reduction in humans remains to be demonstrated; the human evidence is observational and retrospective.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1073/pnas.1107411108

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

14 Valid · 1 Not valid · 22 Not checked · 66 Own results and interpretations

59 more claims

Create a free account to see all 103 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 27
  • It may state two separate claims as one. 16

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 58 references

Cited by

See all 377

Metadata

Authors
Cirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., Kim, J., Morris, J. C., Mintun, M. A., & Sheline, Y. I.
Affiliations
  • Washington University in St. Louis (US)
  • Psychiatry,
  • Departments of aNeurology,
  • and eBiostatistics,
  • Radiology,
  • Eli Lilly (United States) (US)
Venue
Proceedings of the National Academy of Sciences
Published
2011-08-22
Volume
108
Issue
36
Pages
14968-14973
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1977085392
Cited by
377
References
59
Citations by year
2026: 20 · 2025: 32 · 2024: 37 · 2023: 22 · 2022: 30 · 2021: 33 · 2020: 31 · 2019: 26 · 2018: 31 · 2017: 24 · 2016: 29 · 2015: 12 · 2014: 19 · 2013: 19 · 2012: 9
FWCI
5.76
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (and K24, 5p30ns069329-02, NS069329)
  • U.S. Public Health Service (K24MHO79510)
  • National Institute on Aging (K01AG029524, P50AG005681, P01AG003991)
  • National Institute of Mental Health (R21MH077124, K24MH079510)
  • National Institute of Neurological Disorders and Stroke (P30-NS069329)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
serotonin signaling, amyloid-beta, amyloid plaques, Alzheimer's disease, selective serotonin reuptake inhibitors, citalopram, ERK signaling, brain interstitial fluid, hippocampus, antidepressant use, Pittsburgh compound B, amyloid PET, transgenic mouse model, cognitively normal elderly
MeSH terms
Alzheimer Disease, Aniline Compounds, Animals, Brain, Female, Humans, Male, Mice, Transgenic, Radiography, Serotonin, Thiazoles, Time Factors, Citalopram, Signal Transduction, Amyloid beta-Peptides, Antidepressive Agents, Second-Generation, Positron-Emission Tomography, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. https://app.cochat.ai/papers/10.1073/pnas.1107411108
The paper
Cirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., Kim, J., Morris, J. C., Mintun, M. A., & Sheline, Y. I. (2011). Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1107411108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.